Cargando…

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Zhao, Guo, Wang, Shuhang, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213180/ https://www.ncbi.nlm.nih.gov/pubmed/37250972 http://dx.doi.org/10.1016/j.omto.2023.05.001

Ejemplares similares

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
por: Hamdan, Firas, et al.
Publicado: (2023)

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
por: Hamdan, Firas, et al.
Publicado: (2021)

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Publicado: (2021)

IGE AND IGGA ANTIBODY-MEDIATED RELEASE OF HISTAMINE FROM RAT PERITONEAL CELLS : II. INTERACTION OF IGGA AND IGE AT THE TARGET CELL
por: Bach, Michael K., et al.
Publicado: (1971)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

Clinical applications of PD-L1 bioassays for cancer immunotherapy
por: Liu, Delong, et al.
Publicado: (2017)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Engineered IgG1‐Fc – one fragment to bind them all
por: Lobner, Elisabeth, et al.
Publicado: (2016)

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
por: Huang, Zhaoliang, et al.
Publicado: (2022)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

A tail of two ITAMs: GPVI/FcRγ and FcγRIIa's role in platelet activation and thrombus stability
por: Neeves, Keith B.
Publicado: (2021)

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2023)

Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2012)

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
por: Dekkers, Gillian, et al.
Publicado: (2016)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Engineering autoreactive T and B cell responses toward active immunotherapy for inflammatory diseases
por: Chang, Jason Y. H., et al.
Publicado: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Que, Yi, et al.
Publicado: (2021)

Fcγ Receptors and Cross-Presentation in Dendritic Cells
por: Amigorena, Sebastian
Publicado: (2002)

Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
por: Bailey, Elizabeth M., et al.
Publicado: (2021)

IGE AND IGGA ANTIBODY-MEDIATED RELEASE OF HISTAMINE FROM RAT PERITONEAL CELLS : I. OPTIMUM CONDITIONS FOR IN VITRO PREPARATION OF TARGET CELLS WITH ANTIBODY AND CHALLENGE WITH ANTIGEN
por: Bach, Michael K., et al.
Publicado: (1971)

Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy
por: Wang, Beilei, et al.
Publicado: (2022)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding
por: Wang, Chunyu, et al.
Publicado: (2017)

Identity of the elusive IgM Fc receptor (FcμR) in humans
por: Kubagawa, Hiromi, et al.
Publicado: (2009)

Mapping of the binding site for FcμR in human IgM-Fc
por: Nyamboya, Rosemary A., et al.
Publicado: (2020)

Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
por: Mitropoulou, Alkistis N., et al.
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

Synthesis and optimization of photothermal properties of NIR emitting LiGa(5)O(8): Cr(3+) and gold nanorods as hybrid materials for theranostic applications
por: Belman-Rodriguez, C., et al.
Publicado: (2022)

Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
por: Saxena, Abhishek, et al.
Publicado: (2016)

Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering
por: Lee, Hui Sun, et al.
Publicado: (2017)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aiqn9tql0jlmsa9kagpafe1emb